{"log_id": 2950394109369041636, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 1.6e-05, "average": 0.995182, "min": 0.989053}, "location": {"width": 115, "top": 152, "height": 28, "left": 160}, "words": "【儿童用药】"}, {"probability": {"variance": 2.1e-05, "average": 0.997433, "min": 0.979727}, "location": {"width": 537, "top": 189, "height": 33, "left": 205}, "words": "18岁以下的患者用本品的安全性和有效性尚未经研究确定"}, {"probability": {"variance": 7e-06, "average": 0.997221, "min": 0.992545}, "location": {"width": 117, "top": 239, "height": 27, "left": 159}, "words": "【老年用药"}, {"probability": {"variance": 2.9e-05, "average": 0.996047, "min": 0.973217}, "location": {"width": 855, "top": 272, "height": 38, "left": 202}, "words": "据文献报道:帕洛诺司琼在1374名成年癌症患者的临床研究中,其中,316(23%)例≥65"}, {"probability": {"variance": 0.000152, "average": 0.994112, "min": 0.945638}, "location": {"width": 907, "top": 313, "height": 40, "left": 155}, "words": "岁,71例(5%)≥75岁。除某些老年个体较为敏感以外,帕洛诺司琼用于老年患者与年轻患者"}, {"probability": {"variance": 1.7e-05, "average": 0.997235, "min": 0.977126}, "location": {"width": 811, "top": 357, "height": 38, "left": 156}, "words": "在安全性和有效性方面无差别。因此,老年患者用帕洛诺司琼无需调整剂量和特殊监护"}, {"probability": {"variance": 5e-06, "average": 0.997572, "min": 0.993549}, "location": {"width": 158, "top": 408, "height": 28, "left": 162}, "words": "【药物相互作用】"}, {"probability": {"variance": 2.2e-05, "average": 0.997959, "min": 0.975537}, "location": {"width": 863, "top": 442, "height": 40, "left": 199}, "words": "帕洛诺司琼的体内消除途径包括经肾分泌及多种CYP酶参与的。体外进一步研究表明,帕洛"}, {"probability": {"variance": 0.009417, "average": 0.962938, "min": 0.427215}, "location": {"width": 902, "top": 487, "height": 38, "left": 158}, "words": "诺司琼既不是CYP1A2、CYP2A6、CYP2B6、CYP2C9、CYP2D6、CYP2E和CP3A5CYP2C19未研究)"}, {"probability": {"variance": 0.005441, "average": 0.964397, "min": 0.663917}, "location": {"width": 905, "top": 528, "height": 43, "left": 158}, "words": "的抑制剂,也不锈导CYP1A2、CYP2D6或CYP3A4/5的活性。因此与满同琼产生明显的临床"}, {"probability": {"variance": 3e-06, "average": 0.998166, "min": 0.993755}, "location": {"width": 257, "top": 582, "height": 27, "left": 159}, "words": "药物相互作用的可能性很低"}, {"probability": {"variance": 0.013048, "average": 0.965449, "min": 0.39493}, "location": {"width": 869, "top": 607, "height": 51, "left": 197}, "words": "健康志愿者同时静脉注射0.25mg帕洛诺司琼和20mg地塞米松后,没有出现种药物间药代"}, {"probability": {"variance": 0.00016, "average": 0.994197, "min": 0.932679}, "location": {"width": 904, "top": 659, "height": 38, "left": 159}, "words": "动力学上的相互作用。另一项在健康志愿者上进行的药物相互作用的临床试验表明,第一日静脉"}, {"probability": {"variance": 0.000268, "average": 0.991382, "min": 0.908778}, "location": {"width": 574, "top": 706, "height": 33, "left": 159}, "words": "注射0.25mg帕洛诺司琼,同时连续三天口服(125mg/80mg/8"}, {"probability": {"variance": 0.000124, "average": 0.993122, "min": 0.963318}, "location": {"width": 278, "top": 703, "height": 26, "left": 785}, "words": "阿瑞匹坦,对帕洛诺司琼药代"}, {"probability": {"variance": 0.000235, "average": 0.990804, "min": 0.949283}, "location": {"width": 544, "top": 748, "height": 33, "left": 159}, "words": "动力学没有显著改变(AUC:没有改变,Cmax:升高15%)"}, {"probability": {"variance": 0.001039, "average": 0.991591, "min": 0.787686}, "location": {"width": 827, "top": 786, "height": 38, "left": 200}, "words": "健康志愿者单剂量静脉给予0.75mg的帕洛诺司琼,稳定期口服胃复安(每天四次,每次1"}, {"probability": {"variance": 1e-06, "average": 0.999038, "min": 0.996498}, "location": {"width": 364, "top": 834, "height": 33, "left": 160}, "words": "的研究中未发现明显的药代动力学影响"}, {"probability": {"variance": 5e-06, "average": 0.998677, "min": 0.988819}, "location": {"width": 865, "top": 873, "height": 36, "left": 201}, "words": "临床研究表明,帕洛诺司琼能安全地与皮质类固醇类、镇痛药、止吐药、解痉药和抗胆碱能"}, {"probability": {"variance": 1e-06, "average": 0.998516, "min": 0.997105}, "location": {"width": 129, "top": 924, "height": 28, "left": 161}, "words": "药物一起应用"}, {"probability": {"variance": 3.1e-05, "average": 0.996658, "min": 0.976577}, "location": {"width": 864, "top": 958, "height": 37, "left": 203}, "words": "鼠肿瘤模型研究表明,帕洛诺司琼不会抑制所研究的五种化疗药物(顺铂、环磷酰胺、阿糖"}, {"probability": {"variance": 8.6e-05, "average": 0.996046, "min": 0.958813}, "location": {"width": 380, "top": 1005, "height": 34, "left": 162}, "words": "胞苷、阿霉素和丝裂霉素C)的抗癌活性"}, {"probability": {"variance": 1e-06, "average": 0.998098, "min": 0.99683}, "location": {"width": 116, "top": 1052, "height": 27, "left": 169}, "words": "【药物过量】"}, {"probability": {"variance": 0.000159, "average": 0.995156, "min": 0.927595}, "location": {"width": 862, "top": 1084, "height": 37, "left": 204}, "words": "尚无已知的帕洛诺司琼的解毒剂,因此药物过量时应该用支持疗法。在帕洛诺司琼剂量探索"}, {"probability": {"variance": 0.004975, "average": 0.979654, "min": 0.546274}, "location": {"width": 900, "top": 1126, "height": 39, "left": 162}, "words": "研究中,50名成人癌症患者给予90ug/kg的剂量(相当于6mg的固定剂量),接近推荐剂量0.25mg"}, {"probability": {"variance": 6.1e-05, "average": 0.99589, "min": 0.962968}, "location": {"width": 903, "top": 1168, "height": 38, "left": 163}, "words": "的25倍。该剂量组产生的不良反应事件与其它剂量组相似,未见剂量依赖性。尽管未进行过透析"}, {"probability": {"variance": 4e-06, "average": 0.998608, "min": 0.99247}, "location": {"width": 902, "top": 1211, "height": 37, "left": 164}, "words": "治疗的研究,但是由于帕洛诺司琼具有较大的分布容积,故透析不可能作为有效的治疗药物过量"}, {"probability": {"variance": 0.000218, "average": 0.995623, "min": 0.898699}, "location": {"width": 903, "top": 1254, "height": 38, "left": 165}, "words": "手段。大鼠和小鼠单剂量静脉给予帕洛诺司琼的致死量为30mg/kg(按体表面积换算,大鼠和小鼠"}, {"probability": {"variance": 3.8e-05, "average": 0.996168, "min": 0.971122}, "location": {"width": 892, "top": 1297, "height": 39, "left": 166}, "words": "的剂量分别相当于人体推荐剂量的947和474倍),主要中毒症状为惊厥、喘息、肤色苍白、发绀"}, {"probability": {"variance": 4e-06, "average": 0.995267, "min": 0.993198}, "location": {"width": 43, "top": 1353, "height": 24, "left": 167}, "words": "虚脱"}, {"probability": {"variance": 0.001191, "average": 0.982624, "min": 0.905589}, "location": {"width": 112, "top": 1396, "height": 25, "left": 174}, "words": "【临床试验】"}, {"probability": {"variance": 4.3e-05, "average": 0.99717, "min": 0.97286}, "location": {"width": 322, "top": 1434, "height": 30, "left": 208}, "words": "以下数据主要来自于国外研究文献"}, {"probability": {"variance": 0.003977, "average": 0.981448, "min": 0.621652}, "location": {"width": 859, "top": 1471, "height": 34, "left": 209}, "words": "在三项III期临床研究和一个II期临床研究中,分别评价了帕洛诺司琼单剂量注射剂预防中"}, {"probability": {"variance": 0.001343, "average": 0.993398, "min": 0.758943}, "location": {"width": 899, "top": 1515, "height": 34, "left": 168}, "words": "度和重度致吐化疗导致的急性和延迟性恶心呕吐的治疗效果;在这些双盲临床研究中,评价化疗"}, {"probability": {"variance": 0.000492, "average": 0.99226, "min": 0.866846}, "location": {"width": 898, "top": 1556, "height": 36, "left": 170}, "words": "后至少120hr的完全缓解率(无呕吐发作和不需药物治疗)和其它疗效参数;以及进行重复化疗"}], "language": 3}